全文获取类型
收费全文 | 19420篇 |
免费 | 1632篇 |
国内免费 | 713篇 |
专业分类
耳鼻咽喉 | 41篇 |
儿科学 | 199篇 |
妇产科学 | 144篇 |
基础医学 | 1839篇 |
口腔科学 | 656篇 |
临床医学 | 1347篇 |
内科学 | 1923篇 |
皮肤病学 | 229篇 |
神经病学 | 830篇 |
特种医学 | 763篇 |
外国民族医学 | 3篇 |
外科学 | 1275篇 |
综合类 | 3524篇 |
一般理论 | 1篇 |
预防医学 | 1557篇 |
眼科学 | 1837篇 |
药学 | 3458篇 |
9篇 | |
中国医学 | 1833篇 |
肿瘤学 | 297篇 |
出版年
2024年 | 30篇 |
2023年 | 321篇 |
2022年 | 457篇 |
2021年 | 824篇 |
2020年 | 740篇 |
2019年 | 564篇 |
2018年 | 617篇 |
2017年 | 713篇 |
2016年 | 700篇 |
2015年 | 686篇 |
2014年 | 1132篇 |
2013年 | 1482篇 |
2012年 | 1029篇 |
2011年 | 1128篇 |
2010年 | 908篇 |
2009年 | 817篇 |
2008年 | 913篇 |
2007年 | 867篇 |
2006年 | 843篇 |
2005年 | 749篇 |
2004年 | 681篇 |
2003年 | 588篇 |
2002年 | 467篇 |
2001年 | 506篇 |
2000年 | 428篇 |
1999年 | 345篇 |
1998年 | 321篇 |
1997年 | 302篇 |
1996年 | 295篇 |
1995年 | 293篇 |
1994年 | 262篇 |
1993年 | 256篇 |
1992年 | 197篇 |
1991年 | 178篇 |
1990年 | 150篇 |
1989年 | 141篇 |
1988年 | 121篇 |
1987年 | 101篇 |
1986年 | 70篇 |
1985年 | 112篇 |
1984年 | 90篇 |
1983年 | 54篇 |
1982年 | 54篇 |
1981年 | 46篇 |
1980年 | 34篇 |
1979年 | 40篇 |
1978年 | 27篇 |
1977年 | 22篇 |
1976年 | 21篇 |
1972年 | 10篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
Lipid nanoparticles (LNPs) are becoming popular as a means of delivering therapeutics, including those based on nucleic acids and mRNA. The mRNA-based coronavirus disease 2019 vaccines are perfect examples to highlight the role played by drug delivery systems in advancing human health. The fundamentals of LNPs for the delivery of nucleic acid- and mRNA-based therapeutics, are well established. Thus, future research on LNPs will focus on addressing the following: expanding the scope of drug delivery to different constituents of the human body, expanding the number of diseases that can be targeted, and studying the change in the pharmacokinetics of LNPs under physiological and pathological conditions. This review article provides an overview of recent advances aimed at expanding the application of LNPs, focusing on the pharmacokinetics and advantages of LNPs. In addition, analytical techniques, library construction and screening, rational design, active targeting, and applicability to gene editing therapy have also been discussed. 相似文献
4.
目的 对比研究朝鲜淫羊藿酸性多糖酯化还原前后的理化特性,并探讨其改善油酸诱导的肝癌HepG2细胞脂质堆积活性的差异。方法 采用高效凝胶渗透色谱法测定朝鲜淫羊藿酸性多糖(EFPA)的均一性和分子量,高效液相色谱法测定EFPA和酯化还原后朝鲜淫羊藿酸性多糖(EFPA-R)的单糖组成;采用油酸(OA)处理HepG2细胞诱导建立脂质蓄积模型,不同浓度EFPA与EFPA-R(10、30、100、300 μg·mL-1)分别和OA共同作用于细胞24 h,采用CCK-8试剂盒测定细胞存活率,油红O染色观察细胞内脂滴蓄积情况,并采用试剂盒测定细胞内总胆固醇(TC)、甘油三酯(TG)含量。结果 EFPA为成分均一的多糖组分,分子量为125.8 kDa,由甘露糖、葡萄糖、半乳糖、葡萄糖醛酸和阿拉伯糖组成,摩尔比为1.7∶7.4∶1.4∶1.8∶1.0,葡萄糖占比最大,EFPA-R由甘露糖、葡萄糖、半乳糖和阿拉伯糖组成,摩尔比为0.8∶10.6∶2.1∶1.0;在10-300 μg·mL-1范围内,EFPA和EFPA-R对HepG2细胞的抑制作用较弱,作为给药浓度;与空白组相比,模型组细胞中TC、TG含量显著升高(P < 0.01),细胞内红色脂滴显著增多,与模型组相比,EFPA可显著降低细胞中TC、TG含量(P < 0.01),明显减少细胞内红色脂滴(P < 0.05或P < 0.01),EFPA-R干预后细胞则无明显变化。结论 EFPA可明显改善HepG2细胞脂质堆积情况,且呈现剂量依赖性,而半乳糖醛酸(GalA)的存在可能是其抑制HepG2细胞脂质蓄积的关键因素。 相似文献
5.
《Seminars in Arthroplasty》2022,32(4):681-687
BackgroundThe objective of this study was to compare complication rates between patients undergoing reverse shoulder arthroplasty (RSA) after a prior open reduction and internal fixation (ORIF) for proximal humerus fracture (PHF) to those undergoing RSA as a primary treatment for PHFs, glenohumeral osteoarthritis, or rotator cuff tear arthropathy (CTA).MethodsPatients who underwent RSA between 2015 and 2020 were identified in the Mariner database. Patients were separated into 3 mutually exclusive groups: (1) RSA for osteoarthritis, rotator cuff tear, or CTA (Control-RSA); (2) RSA as a primary treatment for PHF (PHF-RSA); and (3) RSA for patients with prior ORIF of PHFs (ORIF-RSA). Ninety-day medical and 2-year postoperative surgical complications were identified. In addition, patients in the PHF-RSA group were subdivided into those undergoing RSA for PHF within 3 months of the fracture (acute) vs. those treated greater than 3 months from diagnosis (delayed). Multivariate regression was performed to control for differences in comorbidities and demographics.ResultsA total of 30,824 patients underwent primary RSA for arthritis or CTA, 5389 patients underwent RSA as a primary treatment for a PHF, and 361 patients underwent RSA after ORIF of a PHF. ORIF before RSA was associated with an increased risk of overall revision (odds ratio [OR] 2.45, P = .002), infection (OR 2.40, P < .001), instability (OR 2.43, P < .001), fracture (OR 3.24, P = .001), minor medical complications (OR 1.59, P = .008), and readmission (OR 2.55, P = .001) compared with the Control-RSA cohort. RSA as a primary treatment for PHF was associated with an increased risk of 2-year revision (OR 1.60, P < .001), infection (OR 1.51, P < .001), instability (OR 2.84, P < .001), and fracture (OR 2.54, P < .001) in addition to major medical complications (OR 2.02, P < .001), minor medical complications (OR 1.92, P < .001), 90-day emergency department visits (OR 1.26, P < .001) and 90-day readmission (OR 2.03, P < .001) compared with the Control-RSA cohort. The ORIF-RSA group had an increased risk of periprosthetic infection (OR 1.94, P = .002) when compared with the PHF-RSA cohort. There were no differences in medical or surgical complications in the RSA-PHF cohort between patients treated in an acute or delayed fashion.ConclusionRSA following ORIF of a PHF is associated with increased complications compared with patients undergoing RSA for nonfracture indications. Prior ORIF of a PHF is also an independent risk factor for postoperative infection after RSA compared with patients who undergo RSA as a primary operation for fracture. The timing of RSA as a primary operation for PHF does not appear to impact the rates of postoperative medical and surgical complications. 相似文献
6.
7.
8.
9.
10.